Lifeline Biotechnologies(LLBO)
$0.000.00 (0.00%)
LLBO
Lifeline Biotechnologies financials statements
$0.00
At close:0.00 (0.00%)
Lifeline Biotechnologies (LLBO) Ratios
35 Followers
Lifeline Biotechnologies Ratios
LLBO's free cash flow for Q? was ―. For the fiscal year, LLBO's free cash flow was increased by ― and operating cash flow was ―. See a summary of the company’s cash flow.
| Ratios | Dec 18 | Dec 17 |
|---|---|---|
| Liquidity Ratios | ||
| Current Ratio | 0.46 | 0.47 |
| Quick Ratio | 0.46 | 0.47 |
| Cash Ratio | 0.00 | 0.00 |
| Solvency Ratio | 0.31 | 0.60 |
| Operating Cash Flow Ratio | 0.36 | 0.11 |
| Short-Term Operating Cash Flow Coverage | 0.43 | 0.12 |
| Net Current Asset Value | $ -207.97K | $ -214.21K |
| Leverage Ratios | ||
| Debt-to-Assets Ratio | 0.74 | 0.76 |
| Debt-to-Equity Ratio | 5.93 | 3.89 |
| Debt-to-Capital Ratio | 0.86 | 0.80 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 |
| Financial Leverage Ratio | 7.99 | 5.11 |
| Debt Service Coverage Ratio | -0.13 | 0.63 |
| Interest Coverage Ratio | 0.00 | 0.00 |
| Debt to Market Cap | 0.03 | 0.06 |
| Interest Debt Per Share | 0.00 | 0.00 |
| Net Debt to EBITDA | -7.53 | 1.58 |
| Profitability Margins | ||
| Gross Profit Margin | 0.00% | 99.82% |
| EBIT Margin | 0.00% | 69.12% |
| EBITDA Margin | 0.00% | 69.30% |
| Operating Profit Margin | 0.00% | 69.12% |
| Pretax Profit Margin | 0.00% | 69.12% |
| Net Profit Margin | 0.00% | 69.12% |
| Continuous Operations Profit Margin | 0.00% | 69.12% |
| Net Income Per EBT | 100.00% | 100.00% |
| EBT Per EBIT | 100.00% | 100.00% |
| Return on Assets (ROA) | -9.84% | 48.06% |
| Return on Equity (ROE) | -78.59% | 245.37% |
| Return on Capital Employed (ROCE) | -78.60% | 245.36% |
| Return on Invested Capital (ROIC) | -11.35% | 50.18% |
| Return on Tangible Assets | -9.84% | 48.06% |
| Earnings Yield | -0.43% | 4.06% |
| Efficiency Ratios | ||
| Receivables Turnover | 0.00 | 1.86 |
| Payables Turnover | 0.00 | 0.03 |
| Inventory Turnover | 0.00 | 0.47 |
| Fixed Asset Turnover | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.70 |
| Working Capital Turnover Ratio | 0.00 | -1.05 |
| Cash Conversion Cycle | 0.00 | -11353.12 |
| Days of Sales Outstanding | 0.00 | 195.94 |
| Days of Inventory Outstanding | 0.00 | 776.35 |
| Days of Payables Outstanding | 0.00 | 12325.41 |
| Operating Cycle | 0.00 | 972.29 |
| Cash Flow Ratios | ||
| Operating Cash Flow Per Share | 0.00 | 0.00 |
| Free Cash Flow Per Share | 0.00 | 0.00 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | 0.43 | 0.12 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.13 |
| Free Cash Flow Yield | 1.39% | 0.76% |
| Valuation Ratios | ||
| Price-to-Earnings (P/E) Ratio | -231.50 | 24.65 |
| Price-to-Sales (P/S) Ratio | 0.00 | 17.04 |
| Price-to-Book (P/B) Ratio | 181.95 | 60.49 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 71.84 | 131.89 |
| Price-to-Operating Cash Flow Ratio | 71.84 | 131.89 |
| Price-to-Earnings Growth (PEG) Ratio | 2.03 | 0.00 |
| Enterprise Value Multiple | -239.02 | 26.17 |
| Enterprise Value | 10.37M | 6.35M |
| EV to EBITDA | -239.02 | 26.17 |
| EV to Sales | 0.00 | 18.13 |
| EV to Free Cash Flow | 74.17 | 140.36 |
| EV to Operating Cash Flow | 74.17 | 140.36 |
| Tangible Book Value Per Share | 0.00 | 0.00 |
| Shareholders’ Equity Per Share | 0.00 | 0.00 |
| Tax and Other Ratios | ||
| Effective Tax Rate | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 |
| Net Income Per Share | -0.00 | 0.00 |
| Tax Burden | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 |
| Income Quality | -3.22 | 0.19 |
Currency in USD

